Business
Theralase Annouces First Patient Treated in Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
TORONTO, ON / ACCESSWIRE / September 4, 2019 / Theralase ® Technologies Inc. (“...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Annouces First Patient Treated in Phase II Non-Muscle Invasive Bladder Cancer Clinical StudyTORONTO, ON / ACCESSWIRE / September 4, 2019 / Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV:TLT) (OTCQB:TLTFF), a clinical stage biopharmaceutical company developing Anti-Cancer treatments with their light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today that, the first patient has been treated in its Phase II clinical study titled “A Phase II Clinical Study of Intravesical Photodynamic Therapy (“PDT”) in Patients with Bacillus Calmette Guérin (“BCG”) Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC”) or Patients who are Intolerant to BCG Therapy (“Study II”)” at University Health Network (“UHN”) in TorontoThis marks the official launch of Study II which focuses on the treatment of approximately 100 BCG-Unresponsive NMIBC patients presenting with Carcinoma In-Situ (“CIS”) in approximately 20 clinical study sites located in Canada and the US, with a primary endpoint of efficacy at any point in time, measured by Complete Response (“CR”), a secondary endpoint of duration of CR and a tertiary endpoint of safety.Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer, Theralase stated that, “Initiation of patient treatment in our Phase II study is a significant milestone for our Photo Dynamic Therapy (“PDT”) research and development programs. NMIBC is a recurrent and progressive cancer, which Theralase believes it’s TLD-1433 therapy can make a significant difference in. Current standards of care for NMIBC including BCG, chemotherapy and immunotherapy, are not curative in nature and unfortunately are associated with considerable morbidity. This underscores the urgent need for new treatment options like Theralase’s TLD-1433 PDT for patients contending with this debilitating and fatal disease.”Shawn Shirazi, Ph.D., CEO - Drug Division, Theralase stated that, “Treating patient one in a pivotal Phase II clinical study commences an exciting journey for the Company aimed to demonstrate to both the public and the scientific community what Theralase is capable...